Stevanato Group at Jefferies Conference: Strategic Growth and Expansion

Stevanato Group (STVN) presented at the Jefferies Global Healthcare Conference 2025, highlighting a doubling of revenue and increased EBITDA over the past five years, driven by a 15% CAGR and a shift towards high-value products now comprising 38% of revenue. The company is expanding capacity, notably with its Fisher plant expected to generate €500 million in revenue by 2028, and is targeting a 30% EBITDA margin by 2027. While expansion in China is paused, Stevanato is addressing potential tariff impacts through client collaboration and may consider equity offerings for additional investments, maintaining a debt-to-EBITDA ratio of 1.2x.

Analysis

Stevanato Group (NYSE:STVN) presented a compelling growth narrative at the Jefferies Global Healthcare Conference 2025, underscoring its robust financial performance and strategic expansion initiatives within the pharmaceutical injectable solutions market. The company has successfully doubled its revenue and increased EBITDA over the past five years, achieving a 15% compound annual growth rate (CAGR), driven significantly by a strategic shift towards high-value products, which now constitute 38% of revenue, up from 17% five years ago. Key to future growth is the Fisher plant in the U.S., which is already operational 24/7, expected to contribute to revenue in 2025, achieve positive gross margins by year-end, and generate €500 million in revenue at full capacity by the end of 2028. Similarly, the Latina plant in Italy is generating positive gross margins and will expand cartridge production by late 2026/early 2027, with a significant contract secured for several hundred million euros per year in cartridge capacity. The company's Q1 2025 results outperformed expectations, particularly in the Biopharmaceutical Delivery Solutions (BDS) segment, with the vial market normalizing post-destocking. Stevanato is targeting continued double-digit growth, a 30% EBITDA margin by 2027, and aims for high-value products to reach 45% of revenue. Expansion in China is currently paused to prioritize the ramp-up of the Fisher and Latina facilities. The company maintains a healthy balance sheet with a debt-to-EBITDA ratio of 1.2x, allowing for potential debt increases up to 2x EBITDA, and may consider equity offerings for further strategic investments. Management is proactively addressing potential tariff impacts through collaboration with clients and suppliers, with no current disruption to order patterns observed.

Key Decisions for Investors

• Investors should consider Stevanato Group's strong historical performance, including a 15% revenue CAGR and a significant increase in high-value product contribution (now 38% of revenue), alongside its ambitious future targets such as a 30% EBITDA margin by 2027, as indicators of a robust growth trajectory.
• The successful ramp-up and achievement of revenue targets at the new Fisher plant (projected €500 million by 2028) and the Latina facility are critical catalysts; progress on these expansions, including gross margin improvements, should be closely monitored.
• Evaluate the company's ability to manage its capital structure effectively, balancing capacity investments with maintaining a manageable debt-to-EBITDA ratio (currently 1.2x, with room to 2x) and the potential for future equity offerings to fund growth.
• Monitor the development of Stevanato's drug delivery device strategy, including proprietary patents and selective contract manufacturing, as this represents a significant long-term growth avenue, particularly as the company aims to become a major player in this market within 5-10 years.
• While the company reports proactive management of potential tariff risks and stable order patterns, investors should remain aware of this as an external factor and track the effectiveness of mitigation strategies.